Non-peptide GLP-1 agonists
Novel non-peptide GLP-1 agonists, pharmaceutical compositions comprising them, use of the non-peptide GLP-1 agonists for the preparation of pharmaceutical compositions and methods for the treatment and/or prevention of disorders and diseases wherein an activation of the human GLP-1 receptor is beneficial, especially metabolic disorders such as IGT, Type 1 diabetes, Type 2 diabetes and obesity.
1. A compound of formula (I);
wherein
R 1 , R 2 , R 3 and R 4 independently are hydrogen, halogen, —CF 3 or —NO 2 , X and V are ═N—,
L is —SO 2 —CH 2 —,
M is —NR 9 —CH 2 , —SO 2 -alkylene, —S-alkylene, —SO-alkylene, —NH—, —NH 2 or a valence bond,
wherein R 9 is hydrogen, lower allyl, cycloalkyl or a heteroaryl which is a 3 to 10 membered ring containing one or more heteroatoms selected from nitrogen, oxygen and sulfur,
in which the cycloalkyl and heteroaryl rings may optionally be substituted with one or more substituents independently selected from halogen, lower alkyl, lower alkanoyl, —OH, —CH 2 OH, —NO 2 , —CN, —C(O)OH, —O-lower alkyl, —C(O)OCH 3 , —C(O)NH 2 , —OCH 2 C(O)NH 2 , —NH 2 , —N(CH 3 ) 2 , —CH(CH 3 ) 2 , —SO 2 NH 2 , —OCHF 2 , —CF 3 and —OCF 3 ,
as well as any optical or geometric isomer or mixture of optical or geometric isomers, or any tautomeric form thereof or a pharmaceutically acceptable salt thereof.
2. A compound of formula (V):
wherein
L is —SO 2 —CH 2 —, —S—, or —SH,
M is —NR 9 —CH 2 , —SO 2 -alkylene, —S-alkylene, —SO-alkylene, —NH—, —NH 2 or a valence bond,
wherein R 9 is hydrogen, lower alkyl, cycloalkyl or a heteroaryl which is a 3 to 10 membered ring containing one or more heteroatoms selected from nitrogen, oxygen and sulfur,
in which the cycloalkyl and heteroaryl rings may optionally be substituted with one or more substituents independently selected from halogen, lower alkyl, lower alkanoyl, —OH, —CH 2 OH, —NO 2 , —CN, —C(O)OH, —O-lower alkyl, —C(O)OCH 3 , —C(O)NH 2 —OCH 2 C(O)NH 2 , —NH 2 , —N(CH 3 ) 2 , —CH 2 N(CH 3 ) 2 , —SO 2 NH 2 , —OCHF 2 , —CF 3 and —OCF 3 ,
A and B independently are hydrogen or lower alkyl,
as well as any optical or geometric isomer or mixture of optical or geometric isomers ar any tautomeric form thereof or a pharmaceutical acceptable salt thereof.
3. A pharmaceutical composition comprising a compound according to claim 1 together with a pharmaceutically acceptable carrier or excipient.
4. A pharmaceutical composition according to claim 3 in unit dosage form, said composition comprising from about 0.05 mg to about 1000 mg of the compound.
5. A method for the treatment of disorders or diseases wherein an activation of the human GLP-1 receptor is beneficial, said method comprising administering to a subject in need thereof an effective amount of a compound of formula (I):
wherein
R 1 , R 2 , R 3 and R 4 independently are hydrogen, halogen, —CF 3 or —NO 2 ,
X and V are ═N—,
L is —SO 2 —CH 2 —, —S—, —SH, —NH 2 or —NH—,
M is —NR 9 —CH 2 , —SO 2 -alkylene, —S-alkylene, —SO-alkylene, —NH—, —NH 2 or a valence bond,
wherein R 9 is hydrogen, lower alkyl, cycloalkyl or a heteroaryl which is a 3 to 10 membered ring containing one or more heteroatoms selected from nitrogen, oxygen and sulfur,
in which the cycloalkyl and heteroaryl rings may optionally be substituted with one or more substituents independently selected from halogen, lower alkyl, lower alkanoyl, —OH, —CH 2 OH, —NO 2 , —CN, —C(O)OH, —O-lower alkyl, —C(O)OCH 3 , —C(O)NH 2 , —OCH 2 C(O)NH 2 , —NH 2 , —N(CH 3 ) 2 , —CH 2 N(CH 3 ) 2 , —SO 2 NH 3 , —OCHF 2 , —CF 3 and —OCF 3 ,
A and B independently are hydrogen or lower alkyl,
as well as any optical or geometric isomer or mixture of optical or geometric isomers, or any tautomeric form thereof or a pharmaceutically acceptable salt thereof.
6. The method according to claim 5 wherein the effective amount of the compound is in the range of from about 0.05 mg to about 2000 mg per day.
7. A pharmaceutical composition according to claim 3 in unit dosage form, said composition comprising from about 0.1 mg to about 500 mg of the compound.
8. A pharmaceutical composition according to claim 3 in unit dosage form, said composition comprising from about 0.5 mg to about 200 mg of the compound.
9. The method according to claim 5 wherein the effective amount of the compound is in the range of from about 0.1 mg to about 1000 mg per day.
10. The method according to claim 5 wherein the effective amount of the compound is in the range of from about 0.5 mg to about 500 mg per day.
11. A pharmaceutical composition comprising a compound according to claim 2 together with a pharmaceutically acceptable carrier or excipient.
12. A pharmaceutical composition according to claim 11 in unit dosage form, said composition comprising from about 0.05 mg to about 1000 mg of the compound.
13. A pharmaceutical composition according to claim 11 in unit dosage form, said composition comprising from about 0.1 mg to about 500 mg of the compound.
14. A pharmaceutical composition according to claim 11 in unit dosage form, said composition comprising from about 0.5 mg to about 200 mg of the compound.
15. A method for the treatment of disorders or diseases wherein an activation of the human GLP-1 receptor is beneficial, said method comprising administering to a subject in need thereof an effective amount of a compound of formula (V):
L is —SO 2 —CH 2 —, —S—, —SH, —NH 2 or —NH—,
M is —NR 9 —CH 2 , —SO 2 -alkylene, —S-alkylene, —SO-alkylene, —NH—, —NH 2 or a valence bond,
wherein R 9 is hydrogen, lower alkyl, cycloalkyl or a heteroaryl which is a 3 to 10 membered ring containing one or more heteroatoms selected from nitrogen, oxygen and sulfur,
in which the cycloalkyl and heteroaryl rings may optionally be substituted with one or more substituents independently selected from halogen, lower alkyl, lower alkanoyl, —OH, —CH 2 OH, —NO 2 , —CN, —C(O)OH, —O-lower alkyl, —C(O)OCH 3 , —C(O)NH 2 , —OCH 2 C(O)NH 2 , —NH 2 , —N(CH 3 ) 2 , —CH 2 N(CH 3 ) 2 , —SO 2 NH 3 , —OCHF 2 , —CF 3 and —OCF 3 ,
A and B independently are hydrogen or lower alkyl,
as well as any optical or geometric isomer or mixture of optical or geometric isomers, or any tautomeric form thereof or a pharmaceutically acceptable salt thereof.
16. The method according to claim 15 wherein the effective amount of the compound is in the range of from about 0.05 mg to about 2000 mg per day.
17. The nod according to claim 15 wherein the effective amount of the compound is in the range of from about 0.1 mg to about 1000 mg per day.
18. The method according to claim 15 wherein the effective amount of the compound is in the range of from about 0.5 mg to about 500 mg per day.
19. A compound selected from the group consisting of
6,7-Dichloro-3-methyl-2-(methylsulfonyl)quinoxaline,
(6,7-Dichloro-3-methylsulfonylquinoxalin-2-yl)amine,
6,7-Dichloro-2-methylsulfonyl-3-(methylsulfonyl)methyl-quinoxaline,
6,7-Dichloro-2-isopropyl-3-(isopropyl-2-sulfonyl)quinoxaline,
6,7-Dichloro-2-isopropyl-3-(methylsulfonyl)quinoxaline,
6,7-Dichloro-2-(isopropylsulfonyl)-3-[(isopropylsulfonyl)methyl]quinoxaline,
6,7-Dichloro-2-isobutyl-3-(methylsulfonyl)quinoxaline,
2-(Sec-butyl)-6,7-dichloro-3-(methylsulfonyl)quinoxaline,
N-[6,7-Dichloro-3-methylsulfonyl)-2-quinoxalinyl]-N-isopropylamine,
N-(6,7-Dichloro-3-(methylsulfonyl)-2-quinoxalinyl)-N-methyl-N-isopropylamine,
N-(6,7-Dichloro-3-(methylsulfonyl)-2-quinoxalinyl)-ethylamine,
N-(6,7-Dichloro-3-(methylsulfonyl)-2-quinoxalinyl)-N,N-dimethylamine,
6,7-Dichloro-3-ethyl-2-(methylsulfonyl)quinoxaline,
6,7-Dichloro-2-(methylsulfonyl)-3-hexylquinoxaline,
6,7-Dichloro-2-(methylsulfonyl)-3-propylquinoxaline,
6,7-Dichloro-2-(isopropylsulfonyl)-3-propylquinoxaline,
N-[6,7-Dichloro-3-(methylsulfonyl)-2-quinoxalinyl]-N-tert-butylamine,
N-[6,7-Dichloro-3-methylsulfonyl)-2-quinoxalinyl]-N-isobutylamine,
5,6,7,8-Tetrachloro-2-isopropyl-3-(methylsulfonyl)quinoxaline,
(6,7-Dichloro-3-methylsulfonylquinoxalin-2-yl)cyclopropylamine,
(6,7-Dichloro-3-methylsulfonylquinoxalin-2-yl)cyclopentylamine,
(6,7-Dichloro-3-methylsulfonylquinoxalin-2-yl)sec-butylamine,
(6,7-Dichloro-)-3-(methylsulfonylquinoxalin-2-yl)-1-ethylpropylamine;
(7-Chloro-3-(methylsulfonyl)-6-nitroquinoxalin-2-yl)sec-butylamine,
(6-Chloro-3-methylsulfonyl-7-nitro-8-trifluoromethylquinoxalin-2-yl)isopropylamine,
(6,7-Dichloro-3-(methylsulfonyl)-quinoxalin-2-yl)tert-pentylamine,
6,7-Dichloro-2-(isopropylsulfanyl)-3-(methylsulfonyl)quinoxaline,
(5-Chloro-3-methylsulfonyl-7-trifluoromethyl-2-quinoxalin-2-yl)-tert-butylamine,
(3-Methylsulfonyl-6,7-dinitroquinoxalin-2-yl)-tert-butylamine,
6-Chloro-2-(3-methylbutylsulfonyl)quinoxaline,
(6,7-Dichloro-3-methanesulfonylquinoxalin-2-yl)-[2-(2,4-dichlorophenyl)ethyl]amine,
(6,7-Dichloro-3-methanesulfonylquinoxalin-2-yl)-[2-(3-fluorophenyl)ethyl]amine,
3-[2-(6,7-Dichloro-3-methanesulfonyl-quinoxalin-2-ylamino)ethyl]phenol,
(6,7-Dichloro-3-methanesulfonylquinoxalin-2-yl)-[2-(3-fluorophenyl)ethyl]amine,
(6,7-Dichloro-3-methanesulfonylquinoxalin-2-yl)dimethylamine,
6,7-Dichloro-2-isopropylsulfanyl-3-methanesulfonylquinoxaline,
(6-Chloro-3-methanesulfonylquinoxalin-2-yl)dimethylamine,
6,7-Dichloro-3-isopropylsulfanyl-3-methanesulfonylquinoxaline,
(6,7-Dichloro-3-methanesulfonylquinoxalin-2-yl)-[2-(2,4-dichlorophenyl)ethyl]amine,
(6,7-Dichloro-3-methanesulfonylquinoxalin-2-yl)-[2-(2-fluorophenyl)ethyl]amine,
3-[2-(6,7-Dichloro-3-methanesulfonyl-quinoxalin-2-ylamino)ethyl]phenol,
(6,7-Dichloro-3-methanesulfonylquinoxalin-2-yl)-[2-(3-fluorophenyl)ethyl]amine,
(6,7-Dichloro-3-methanesulfonylquinoxalin-2-yl)dimethylamine,
6,7-Dichloro-2-isopropylsulfanyl-3-methanesulfonylquinoxaline,
(6-Chloro-3-methanesulfonylquinoxalin-2-yl)dimethylamine, and
6-Chloro-3-isopropylsulfanyl-2-methanesulfonylquinoxaline
as well as any optical or geometric isomer or mixture of optical or geometric isomers, or any tautomeric form therof or a pharmaceutically acceptable salt thereof.
20. A pharmaceutical composition comprising a compound according to claim 19 together with a pharmaceutically acceptable carrier or excipient.
21. A pharmaceutical composition according to claim 20 in unit dosage form, said composition comprising from about 0.05 mg to about 1000 mg of the compound.
22. A pharmaceutical composition according to claim 20 in unit dosage form, said composition comprising from about 0.1 mg to about 500 mg of the compound.
23. A pharmaceutical composition according to claim 20 in unit dosage form, said composition comprising from about 0.5 mg to about 200 mg of the compound.
24. A method for the treatment of disorders or diseases wherein an activation of the human GLP-1 receptor is beneficial, said method comprising administering to a subject in need thereof an effective amount of a compound of claim 19 .
25. The method according to claim 24 wherein the effective amount of the compound is in the range of from about 0.05 mg to about 2000 mg per day.
26. The method according to claim 24 wherein the effective amount of the compound is in the range of from about 0.1 mg to about 1000 mg per day.
27. The method according to claim 24 wherein the effective amount of the compound is in the range of from about 0.5 mg to about 500 mg per day.